Team involved in Reolysin IND trial receives prestigious award
May 27, 2014
Dr. Derek Jonker, Saara Ali and their 20-member team have been awarded the “Early Drug Development Team Award” by the National Cancer Institute of Canada for their work on the Reolysin IND (Investigational New Drug) trial involving metastatic colorectal cancer patients. The award recognizes the research teams' outstanding contribution toward the number of patients enrolled in the study, ethics compliance, timeliness of data entry and overall team work. Reolysin is a cancer-fighting virus therapy that is in Phase II clinical trials. This trial is the first to use Reolysin in combination with standard chemotherapy regimes.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.
Communications and Public Relations
Ottawa Hospital Research Institute